PMID- 26306453
OWN - NLM
STAT- MEDLINE
DCOM- 20160318
LR  - 20151130
IS  - 1873-2399 (Electronic)
IS  - 0301-472X (Linking)
VI  - 43
IP  - 12
DP  - 2015 Dec
TI  - Killer immunoglobulin-like receptors can predict TKI treatment-free remission in 
      chronic myeloid leukemia patients.
PG  - 1015-1018.e1
LID - S0301-472X(15)00611-6 [pii]
LID - 10.1016/j.exphem.2015.08.004 [doi]
AB  - Several factors are predictive of treatment-free remission (TFR) in chronic 
      myeloid leukemia (CML), but few data exist on the role of natural killer (NK) 
      cells and their killer-cell immunoglobulin-like receptors (KIRs). KIR and human 
      leukocyte antigen (HLA) genotypes were investigated in 36 CML patients who 
      discontinued tyrosine kinase inhibitor (TKI) treatment after achieving deep 
      molecular response (MR(4.5)). Cumulative TFR was significantly higher in patients 
      homozygous for KIR A haplotype (85.7% vs. 45.5%; p = 0.029). Younger age, Bx 
      haplotype, and the combination KIR3DS1/KIR3DL1 present/HLA-Bw4 present were 
      significantly associated with relapse. KIR genotypes could prove useful in 
      identifying patients that are likely to maintain MR(4.5) after discontinuing TKI 
      treatment.
CI  - Copyright (c) 2015 ISEH - International Society for Experimental Hematology. 
      Published by Elsevier Inc. All rights reserved.
FAU - Caocci, Giovanni
AU  - Caocci G
AD  - Hematology Unit, Department of Medical Sciences, Bone Marrow Transplant Center, 
      R. Binaghi Hospital, University of Cagliari, Cagliari, Italy. Electronic address: 
      giovanni.caocci@unica.it.
FAU - Martino, Bruno
AU  - Martino B
AD  - Division of Hematology, Ospedali Riuniti, Reggio Calabria, Italy.
FAU - Greco, Marianna
AU  - Greco M
AD  - Hematology Unit, Department of Medical Sciences, Bone Marrow Transplant Center, 
      R. Binaghi Hospital, University of Cagliari, Cagliari, Italy.
FAU - Abruzzese, Elisabetta
AU  - Abruzzese E
AD  - Hematology Unit, S. Eugenio Hospital, Tor Vergata University, Rome, Italy.
FAU - Trawinska, Malgorzata Monika
AU  - Trawinska MM
AD  - Hematology Unit, S. Eugenio Hospital, Tor Vergata University, Rome, Italy.
FAU - Lai, Sara
AU  - Lai S
AD  - Medical Genetics, Department of Medical Sciences, Regional Transplant Center, R. 
      Binaghi Hospital, University of Cagliari, Cagliari, Italy.
FAU - Ragatzu, Paola
AU  - Ragatzu P
AD  - Medical Genetics, Department of Medical Sciences, Regional Transplant Center, R. 
      Binaghi Hospital, University of Cagliari, Cagliari, Italy.
FAU - Galimberti, Sara
AU  - Galimberti S
AD  - Department of Clinical and Experimental Medicine, University of Pisa, Pisa, 
      Italy.
FAU - Barate, Claudia
AU  - Barate C
AD  - Department of Clinical and Experimental Medicine, University of Pisa, Pisa, 
      Italy.
FAU - Mulas, Olga
AU  - Mulas O
AD  - Hematology Unit, Department of Medical Sciences, Bone Marrow Transplant Center, 
      R. Binaghi Hospital, University of Cagliari, Cagliari, Italy.
FAU - Labate, Claudia
AU  - Labate C
AD  - Division of Hematology, Ospedali Riuniti, Reggio Calabria, Italy.
FAU - Littera, Roberto
AU  - Littera R
AD  - Medical Genetics, Department of Medical Sciences, Regional Transplant Center, R. 
      Binaghi Hospital, University of Cagliari, Cagliari, Italy.
FAU - Carcassi, Carlo
AU  - Carcassi C
AD  - Medical Genetics, Department of Medical Sciences, Regional Transplant Center, R. 
      Binaghi Hospital, University of Cagliari, Cagliari, Italy.
FAU - Gambacorti Passerini, Carlo
AU  - Gambacorti Passerini C
AD  - Department of Internal Medicine, University of Milano Bicocca, Monza, Italy.
FAU - La Nasa, Giorgio
AU  - La Nasa G
AD  - Hematology Unit, Department of Medical Sciences, Bone Marrow Transplant Center, 
      R. Binaghi Hospital, University of Cagliari, Cagliari, Italy.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
DEP - 20150822
PL  - Netherlands
TA  - Exp Hematol
JT  - Experimental hematology
JID - 0402313
RN  - 0 (KIR3DL1 protein, human)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Receptors, KIR3DL1)
RN  - 0 (Receptors, KIR3DS1)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - *Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug 
      therapy/immunology/mortality
MH  - Male
MH  - Middle Aged
MH  - Protein Kinase Inhibitors/*administration & dosage
MH  - Receptors, KIR3DL1/*immunology
MH  - Receptors, KIR3DS1/*immunology
MH  - Survival Rate
EDAT- 2015/08/27 06:00
MHDA- 2016/03/19 06:00
CRDT- 2015/08/27 06:00
PHST- 2015/06/30 00:00 [received]
PHST- 2015/08/04 00:00 [revised]
PHST- 2015/08/08 00:00 [accepted]
PHST- 2015/08/27 06:00 [entrez]
PHST- 2015/08/27 06:00 [pubmed]
PHST- 2016/03/19 06:00 [medline]
AID - S0301-472X(15)00611-6 [pii]
AID - 10.1016/j.exphem.2015.08.004 [doi]
PST - ppublish
SO  - Exp Hematol. 2015 Dec;43(12):1015-1018.e1. doi: 10.1016/j.exphem.2015.08.004. 
      Epub 2015 Aug 22.